Olaparib treatment reduced AR levels only in BRCA2-knockdown prostate cancer cells, indicating that 6-TG and olaparib regulate AR through different molecular mechanisms, the first being BRCA2-independent and the second BRCA2-dependent. Here, BRCA2 is linked to prostate carcinoma.